Optimal use of lenvatinib in the treatment of advanced thyroid cancer

DOI: 10.1186/s41199-017-0026-0

Keywords: Adverse event, Lenvatinib, Multitargeted kinase inhibitor, Thyroid cancer, Vascular endothelial growth factor receptor

Full-Text   Cite this paper   Add to My Lib

Abstract:

Summary of efficacy in clinical trials of lenvatinib in the treatment of thyroid cance

Full-Text